RHY 5.26% 5.4¢ rhythm biosciences limited

Ann: Strategy & Market Update, page-5

  1. 451 Posts.
    lightbulb Created with Sketch. 174
    Start all over again and previous approvals are void. What a shame that this company has been so poorly run.
    The product with so much potential may never see any clinical use. I am starting to realize after 30 years of investing
    that management's ability is as important as any potential product.
    Bill
 
watchlist Created with Sketch. Add RHY (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.